NCT00766246View on ClinicalTrials.gov

Phase II Avastin Trial for Stage IIIB/IV NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Non-small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IV
Interventions
DRUG

bevacizumab

15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance

DRUG

docetaxel

75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment

DRUG

carboplatin

AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment

Sponsors

Lead Sponsor

Pharmatech

Collaborators (2)

Genentech, Inc.
Sanofi
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Pharmatech

INDUSTRY